en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Topic › Structure And Receptor Pharmacology — Beginner to Advanced

Structure And Receptor Pharmacology — Beginner to Advanced

By Editorial Desk · published 2026-08-01 · last reviewed 2026-08-01 · Topic

half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Related pages on this site

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Background from the literature

=== Rehabilitation and exercise === Cardiac rehabilitation benefits many who have experienced myocardial infarction, even if there has been substantial heart damage and resultant left ventricular failure. It should start soon after discharge from the hospital. The program may include lifestyle advice, exercise, social support, as well as recommendations about driving, flying, sports participation, stress management, and sexual intercourse. Returning to sexual activity after myocardial infarction is a major concern for most patients, and is an important area to be discussed in the provision of holistic care. In the short-term, exercise-based cardiovascular rehabilitation programs may reduce the risk of a myocardial infarction, reduces a large number of hospitalizations from all causes, reduces hospital costs, improves health-related quality of life, and has a small effect on all-cause mortality. Longer-term studies indicate that exercise-based cardiovascular rehabilitation programs may reduce cardiovascular mortality and myocardial infarction.

Patrick Simmons – guitars, banjo, recorder, vocals (1970–1982, 1987–1991, 1992, 1993–present) Tom Johnston – vocals, guitars, keyboards, harmonica (1970–1977, 1987–1991, 1992, 1993–present) Michael McDonald – vocals, keyboards, synthesizers (1975–1982, 1987, 1992, 1995–1996, 2019–present) John McFee – guitars, mandolin, banjo, violin, cello, pedal steel guitar, harmonica, vocals (1979–1982, 1987, 1993–present) Current touring members

In intracellular chemistry, sulfur operates as a carrier of reducing hydrogen and its electrons for cellular repair of oxidation. Reduced glutathione, a sulfur-containing tripeptide, is a reducing agent through its sulfhydryl (–SH) moiety derived from cysteine. Sulfur atoms may be catenated on the sulfhydryl groups of cysteine or glutathione to form a hydropersulfide (–SSH), which act as signaling molecules and donors of sulfur atoms in the biosynthesis of iron-sulfur clusters and some sulfur containing metabolites. Polysulfides and elemental sulfur are also known to exist in both prokaryotes and eukaryotes. Methanogenesis, the route to most of the world's methane, is a multistep biochemical transformation of carbon dioxide. This conversion requires several organosulfur cofactors. These include coenzyme M, CH3SCH2CH2SO−3, the immediate precursor to methane.

At 8:32 a.m., FAA officials were notified Flight 11 had been hijacked, and they notified the North American Aerospace Defense Command (NORAD). NORAD scrambled two F-15s from Otis Air National Guard Base in Massachusetts; they were airborne by 8:53 a.m. Because of slow and confused communication from FAA officials, NORAD had nine minutes' notice, and no notice about any of the other flights before they crashed. After both of the Twin Towers had been hit, more fighters were scrambled from Langley Air Force Base in Virginia at 9:30 a.m. At 10:20 am, Vice President Dick Cheney issued orders to shoot down any commercial aircraft that could be positively identified as being hijacked. These instructions were not relayed in time for the fighters to take action. Some fighters took to the air without live ammunition, knowing that to prevent the hijackers from striking their intended targets, the pilots might have to intercept and crash their fighters into the hijacked planes, possibly ejecting at the last moment. For the first time in U.S. history, the emergency preparedness plan Security Control of Air Traffic and Air Navigation Aids (SCATANA) was invoked, stranding tens of thousands of passengers across the world. Ben Sliney, in his first day as the National Operations Manager of the FAA, ordered that American airspace be closed to all international flights, causing about 500 flights to be turned back or redirected to other countries.

Sources: en.wikipedia.org

Further detail

== Clinical trials == In June 2020, CureVac was launched for phase I trial with 280 participants. In August, CureVac was launched for phase II trials with 674 participants. In November, CureVac reported results of a Phase I-II clinical trial that CVnCoV (active ingredient zorecimeran) was well-tolerated, safe, and produced a robust immune response. In December 2020, CureVac began a Phase III clinical trial of CVnCoV with 36,500 participants. Bayer will provide clinical trial support and international logistics for the Phase III trial, and may be involved in eventual manufacturing should the vaccine prove to be safe and effective. In February 2021, the EU's CHMP started a rolling review of CVnCoV. In April 2021, the same procedure began in Switzerland. In June 2021, CureVac announced that the vaccine's efficacy against symptomatic disease is 48%. The company said the high number of variants in circulation may explain the low efficacy, but some scientists attribute the result to insufficient immunogenicity due to the use of unmodified mRNA (the Pfizer–BioNTech and Moderna vaccines use uracil-modified mRNA) or the dose being too low (12 μg, compared to 30 μg for Pfizer–BioNTech and 100 μg for Moderna). Neutralizing antibody levels in CureVac recipients were about the same as those in convalescence, but much lower than those seen in recipients of Pfizer–BioNTech or Moderna. The modified mRNA induces potent antibodies and other protective immune responses and circumvents the body's inflammatory reactions.

According to the Indian naval hydrographic charts, the mainland coastline consists of 43% sandy beaches, 11% rocky shores including cliffs, and 46% mudflats or marshy shores. Coastal features include the marshy Rann of Kutch of western India and the alluvial Sundarbans delta of eastern India, the latter shared with Bangladesh. India has two archipelagos: the Lakshadweep coral atolls off the south-western coast, and the Andaman and Nicobar Islands, a volcanic chain in the Andaman Sea.

=== Viewpoints modeling and the RM-ODP framework === Most complex system specifications are so extensive that no single individual can fully comprehend all aspects of the specifications. Furthermore, we all have different interests in a given system and different reasons for examining the system's specifications. A business executive will ask different questions of a system make-up than would a system implementer. The concept of RM-ODP viewpoints framework, therefore, is to provide separate viewpoints into the specification of a given complex system. These viewpoints each satisfy an audience with interest in a particular set of aspects of the system. Associated with each viewpoint is a viewpoint language that optimizes the vocabulary and presentation for the audience of that viewpoint. Viewpoint modeling has become an effective approach for dealing with the inherent complexity of large distributed systems. Current software architectural practices, as described in IEEE 1471, divide the design activity into several areas of concerns, each one focusing on a specific aspect of the system. Examples include the "4+1" view model, the Zachman Framework, TOGAF, DoDAF and, of course, RM-ODP. A viewpoint is a subdivision of the specification of a complete system, established to bring together those particular pieces of information relevant to some particular area of concern during the analysis or design of the system. Although separately specified, the viewpoints are not completely independent; key items in each are identified as related to items in the other viewpoints.

Phalloidin belongs to a class of toxins called phallotoxins, which are found in mushrooms of the genus Amanita. It is a rigid bicyclic heptapeptide that is lethal after a few days when injected into the bloodstream. The major symptom of phalloidin poisoning is acute hunger due to the destruction of liver cells. It functions by binding and stabilizing filamentous actin (F-actin) and effectively prevents the depolymerization of actin fibers. Due to its tight and selective binding to F-actin, derivatives of phalloidin containing fluorescent tags are used widely in microscopy to visualize F-actin in biomedical research.

== History == Barbituric acid was first synthesized 27 November 1864, by German chemist Adolf von Baeyer, and later perfected in 1879 by the French chemist Edouard Grimaux, who developed and improved the synthesis. This was done by condensing urea with diethyl malonate. There are several stories about how the substance got its name. The most likely story is that Baeyer and his colleagues went to celebrate their discovery in a tavern where the town's artillery garrison were also celebrating the feast of Saint Barbara – the patron saint of artillerymen. An artillery officer is said to have christened the new substance by amalgamating Barbara with urea. Another story holds that Baeyer synthesized the substance from the collected urine of a Munich waitress named Barbara. No substance of medical value was discovered, however, until 1902 when two German scientists working at Bayer, Emil Fischer and Joseph von Mering, discovered that barbital was very effective in putting dogs to sleep. Barbital was then marketed by Bayer under the trade name Veronal. It is said that Mering proposed this name because the most peaceful place he knew was the Italian city of Verona. In 1912, Bayer introduced another barbituric acid derivative, phenobarbital, under the trade name Luminal, as a sedative–hypnotic. It was not until the 1950s that the behavioral disturbances and physical dependence potential of barbiturates became recognized. Since the 1970s, most barbiturates were replaced by benzodiazepines.

Sources: en.wikipedia.org

Supporting material

Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab was approved for medical use in the United States in July 2020, and in the European Union in August 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

This flaw is supported by the FAO/WHO/UNU, who state that BV and NPU are measured when the protein content of the diet is clearly below that of requirement, deliberately done to maximize existing differences in quality as inadequate energy intake lowers the efficiency of protein utilization and in most N balance studies, calorie adequacy is ensured. And because no population derives all of its protein exclusively from a single food, the determination of BV of a single protein is of limited use for application to human protein requirements. Another limitation of the use of Biological Value as a measure of protein quality is that proteins which are completely devoid of one essential amino acid (EAA) can still have a BV of up to 40. This is because of the ability of organisms to conserve and recycle EAAs as an adaptation of inadequate intake of the amino acid. Lastly, the use of rats for the determination of protein quality is not ideal. Rats differ from humans in requirements of essential amino acids. This has led to a general criticism that experiments on rats lead to an over-estimation of the BV of high-quality proteins to man because human requirements of essential amino acids are much lower than those for rats (as rats grow at a much faster rate than humans). Also, because of their fur, rats are assumed to have relatively high requirements of sulphur-containing amino acids (methionine and cysteine). As a result, the analytical method that is universally recognized by the Food and Agriculture Organization (FAO), World Health Organization (WHO), the U.S.

On Stalin's instructions on 5 January 1946, Kimon Georgiev, Damyan Velchev and Anton Yugov met with opposition leaders Nikola Petkov and Kosta Lulchev, but they flatly refused to enter the government, rejecting the legitimacy of the elections and demanding an end to the Communists' terror. On 7 January Georgiev was summoned to Stalin, who sharply criticised him for his soft attitude towards the opposition. On 10 January, Soviet First Deputy Foreign Minister Andrei Vyshinsky met with Petkov and Lulchev in Sofia, but they did not change their position.

This glossary of cellular and molecular biology is a list of definitions of terms and concepts commonly used in the study of cell biology, molecular biology, and related disciplines, including molecular genetics, biochemistry, and microbiology. It is split across two articles:

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

Network